Trial results for The Support, Educate, Empower (SEE) Program, an intervention for Glaucoma patients, were posted on ClinicalTrials.gov on 2025-11-03. The program demonstrated a significant improvement in eye drop medication adherence, increasing mean adherence from 58.0% in the control group to 77.6% in the intervention group over six months.
Background
Glaucoma is a progressive eye condition that can lead to irreversible vision loss if not managed effectively. A cornerstone of glaucoma management is consistent adherence to prescribed eye drop medications, which help lower intraocular pressure. However, maintaining daily medication routines can be challenging for many patients, leading to suboptimal treatment outcomes. The Support, Educate, Empower (SEE) Program was designed to address this critical issue by providing personalized coaching and education, aiming to improve adherence and reduce glaucoma-related distress.
Trial design
This completed study, designated as Phase NA, enrolled 236 participants with Glaucoma. The trial compared the SEE Intervention - Personalized Glaucoma Coaching program against enhanced standard care. The primary objective was to test whether the personalized Glaucoma Coaching Program improves eye drop medication adherence. A secondary outcome aimed to assess whether glaucoma-related distress decreases among SEE program participants.
Key results
The trial reported several key measurements for medication adherence and glaucoma-related distress:
- Mean Percent Electronically Monitored Medication Adherence Over Six Months:
- Participants in the SEE Intervention group achieved a mean adherence of 77.6% (Standard Deviation 19.7).
- Participants in the Enhanced Care Control group achieved a mean adherence of 58.0% (Standard Deviation 25.2).
- Percentage of Participants Who Achieved >= 80% Medication Adherence Over the 6 Month Study Period:
- 62 participants in the SEE Intervention group achieved this threshold.
- 27 participants in the Enhanced Care Control group achieved this threshold.
Statistical analysis indicated a significant difference in medication adherence between the groups, with a Wilcoxon (Mann-Whitney) p-value of 0.001 for mean adherence and a Chi-squared p-value of 0.001 for the percentage of participants achieving >= 80% adherence.
Regarding Change in Glaucoma-related Distress, the trial reported a Mean Difference (Final Values) of -0.3, with a 95.0% Confidence Interval ranging from -0.5 to -0.1, suggesting a reduction in distress in the intervention group compared to control.
What this means
The results of The Support, Educate, Empower (SEE) Program suggest that a personalized coaching intervention can significantly improve eye drop medication adherence in glaucoma patients. The substantial increase in mean adherence and the higher proportion of patients achieving optimal adherence levels could translate into better disease management and potentially slow the progression of vision loss. The observed reduction in glaucoma-related distress also indicates a positive impact on patients' quality of life. These findings highlight the potential value of structured patient support programs in managing chronic conditions like glaucoma.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04735653, titled "The Support, Educate, Empower (SEE) Program", were posted on 2025-11-03 on clinicaltrials.gov.